This study aimed to explore whether the serum level of CEA and CYFRA21-1 can be a prognostic factor after two cycles of adjuvant chemotherapy for NSCLC patients who received complete resection. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.